Takeda signs deal with UK biotech Engitix
The firms will use Engitix’ extracellular matrix (ECM) discovery platform to develop new therapies for fibrotic liver diseases
Read More
Tag: Engitix
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
